Aurovela 1/20

Birth Control, Acne Vulgaris, Folate supplementation therapy + 5 more
Treatment
1 FDA approval
20 Active Studies for Aurovela 1/20

What is Aurovela 1/20

EthinylestradiolThe Generic name of this drug
Treatment SummaryEthinylestradiol is a synthetic form of the female hormone estrogen. It was first developed in 1938, with the goal of creating an estrogen that had better oral absorption. Ethinylestradiol was approved by the FDA in 1943 and is now commonly found in birth control pills as a replacement for mestranol.
LOESTRIN Fe 1.5/30is the brand name
Aurovela 1/20 Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
LOESTRIN Fe 1.5/30
Ethinylestradiol
1973
679

Approved as Treatment by the FDA

Ethinylestradiol, also known as LOESTRIN Fe 1.5/30, is approved by the FDA for 1 uses including Birth Control .
Birth Control
Used to treat Contraception in combination with Levonorgestrel

Effectiveness

How Aurovela 1/20 Affects PatientsEthinylestradiol is a synthetic estrogen that helps to stop ovulation and reduce the growth of the lining in the uterus. It is taken once a day and is generally considered to be a safe drug, with few serious side effects from an overdose. However, patients should be aware of the increased risk of thrombotic events associated with this drug.
How Aurovela 1/20 works in the bodyEthinylestradiol is a synthetic version of the female hormone estrogen. It is used in oral contraceptives to stop ovulation, thicken cervical mucus, and prevent the endometrium from changing in a way that would allow an egg to implant. Ethinylestradiol also lowers levels of luteinizing hormone, which decreases blood flow to the endometrium, and raises levels of sex hormone binding globulin.

When to interrupt dosage

The advocated measure of Aurovela 1/20 is contingent upon the recognized disorder, for example Acne Vulgaris, Hormonal Contraception and Folate supplementation therapy. The dosage fluctuates depending on the technique of delivery featured in the table below.
Condition
Dosage
Administration
Acne Vulgaris
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule - Oral, Capsule
Birth Control
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule - Oral, Capsule
Menopause
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule - Oral, Capsule
Hormonal Contraception
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule - Oral, Capsule
Osteoporosis
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule - Oral, Capsule
Acne Vulgaris
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule - Oral, Capsule
Folate supplementation therapy
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule - Oral, Capsule
Patient desires oral contraception for birth control
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule - Oral, Capsule

Warnings

Aurovela 1/20 Contraindications
Condition
Risk Level
Notes
Heavy Smoking
Do Not Combine
Metrorrhagia
Do Not Combine
estrogen-sensitive cancer
Do Not Combine
Thrombophlebitis
Do Not Combine
Venous Thrombosis
Do Not Combine
Venous Thrombosis
Do Not Combine
Pulse Frequency
Do Not Combine
Breast
Do Not Combine
Coronary Artery Disease
Do Not Combine
high risk of arterial thrombotic disease
Do Not Combine
Thromboembolism
Do Not Combine
Coronary Disease
Do Not Combine
Hypersensitivity
Do Not Combine
Pulse Frequency
Do Not Combine
Adrenal Insufficiency
Do Not Combine
major surgery with prolonged immobilization
Do Not Combine
Pulse Frequency
Do Not Combine
Severe Hypertension
Do Not Combine
undiagnosed abnormal genital bleeding
Do Not Combine
Breast Cancer
Do Not Combine
Liver Neoplasms
Do Not Combine
Deep Vein Thrombosis
Do Not Combine
Fibrosis
Do Not Combine
Breast
Do Not Combine
Renal Insufficiency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Ethinylestradiol may interact with Pulse Frequency
There are 20 known major drug interactions with Aurovela 1/20.
Common Aurovela 1/20 Drug Interactions
Drug Name
Risk Level
Description
Anastrozole
Major
The therapeutic efficacy of Anastrozole can be decreased when used in combination with Ethinylestradiol.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Ethinylestradiol.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Ethinylestradiol.
Belinostat
Major
The metabolism of Belinostat can be increased when combined with Ethinylestradiol.
Binimetinib
Major
The metabolism of Binimetinib can be increased when combined with Ethinylestradiol.
Aurovela 1/20 Toxicity & Overdose RiskWomen who overdose on Levonorgestrel may experience vomiting, abdominal pain, and fatigue. They may also have irregular bleeding, tenderness in their breasts, and become drowsy. Treatment for overdose should include monitoring for potassium, sodium, and signs of metabolic acidosis.

Aurovela 1/20 Novel Uses: Which Conditions Have a Clinical Trial Featuring Aurovela 1/20?

38 active trials are investigating the potential of Aurovela 1/20 to be used as a Folate supplementation therapy, as a treatment for Premenstrual Dysphoric Disorder, and as a Menopause remedy.
Condition
Clinical Trials
Trial Phases
Birth Control
29 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Early Phase 1
Hormonal Contraception
0 Actively Recruiting
Folate supplementation therapy
0 Actively Recruiting
Patient desires oral contraception for birth control
0 Actively Recruiting
Osteoporosis
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Menopause
0 Actively Recruiting

Patient Q&A Section about aurovela 1/20

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the generic name for Aurovela Fe 1 20?

"- Aurovela Fe 1 / 20 (ethinyl estradiol / norethindrone) is a combination birth control pill containing female hormones that prevent ovulation (the release of an egg from an ovary).

Aurovela Fe 1 / 20 is a combination birth control pill containing the female hormones ethinyl estradiol and norethindrone that prevent ovulation."

Answered by AI

What are the side effects of Aurovela Fe 1 20?

"The following side effects may occur: nausea, vomiting, headache, bloating, breast tenderness, swelling of ankles/feet (fluid retention), or weight change. You may also experience vaginal bleeding between periods (spotting) or missed/irregular periods, especially during the first few months of using this medication."

Answered by AI

What kind of birth control is Aurovela 1 20?

"The medication consists of a progestin and an estrogen which work together to prevent pregnancy. In addition to preventing pregnancy, the medication may also make your periods more regular, decrease blood loss and pain during periods, decrease your risk of ovarian cysts, and treat acne."

Answered by AI

Is Aurovela 1/20 A good birth control?

"Aurovela Fe 1/20, a treatment for Birth control, has an average rating of 3.3 out of 10 from 92 reviewers. 21% had a positive experience, while 71% had a negative experience."

Answered by AI

Clinical Trials for Aurovela 1/20

Have you considered Aurovela 1/20 clinical trials? We made a collection of clinical trials featuring Aurovela 1/20, we think they might fit your search criteria.
Have you considered Aurovela 1/20 clinical trials? We made a collection of clinical trials featuring Aurovela 1/20, we think they might fit your search criteria.
Have you considered Aurovela 1/20 clinical trials? We made a collection of clinical trials featuring Aurovela 1/20, we think they might fit your search criteria.